Purple Biotech Stock Today
| PPBT Stock | USD 2.80 0.07 2.56% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Purple Biotech is selling for under 2.80 as of the 18th of March 2025; that is 2.56 percent increase since the beginning of the trading day. The stock's last reported lowest price was 2.7. Purple Biotech has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 18th of December 2024 and ending today, the 18th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of November 2015 | Category Healthcare | Classification Health Care |
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. The company has 2.65 M outstanding shares of which 53.98 K shares are at this time shorted by private and institutional investors with about 2.34 trading days to cover. More on Purple Biotech
Moving together with Purple Stock
Moving against Purple Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Purple Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPurple Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Purple Biotech's financial leverage. It provides some insight into what part of Purple Biotech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Purple Biotech (PPBT) is traded on NASDAQ Exchange in USA. It is located in 4 Oppenheimer Street, Rehovot, Israel, 7670104 and employs 6 people. Purple Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.22 M. Purple Biotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.65 M outstanding shares of which 53.98 K shares are at this time shorted by private and institutional investors with about 2.34 trading days to cover.
Purple Biotech currently holds about 36.02 M in cash with (14.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.0.
Check Purple Biotech Probability Of Bankruptcy
Ownership AllocationRoughly 94.99 pct. of Purple Biotech outstanding shares are held by general public with 1.98 % owned by insiders and only 3.03 (%) by third-party entities.
Check Purple Ownership Details
Purple Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Global Retirement Partners, Llc. | 2024-12-31 | 16.0 | |
| Sound Income Strategies | 2024-09-30 | 0.0 | |
| Venture Visionary Partners Llc | 2024-09-30 | 0.0 | |
| Citadel Advisors Llc | 2024-09-30 | 0.0 | |
| North Star Investment Management Corp | 2024-09-30 | 0.0 | |
| Wealth Advisors Of Iowa, Llc | 2024-09-30 | 0.0 | |
| Geode Capital Management, Llc | 2024-09-30 | 0.0 | |
| Raymond James & Associates | 2024-09-30 | 0.0 | |
| Jpmorgan Chase & Co | 2024-12-31 | 0.0 | |
| Kingswood Wealth Advisors Llc | 2024-12-31 | 33.6 K | |
| Two Sigma Securities, Llc | 2024-12-31 | 15.4 K |
Purple Biotech Historical Income Statement
Purple Stock Against Markets
Purple Biotech Corporate Management
| MA CPA | Chief Officer | Profile | |
| Fabien Sebille | Chief Officer | Profile | |
| Michael Schickler | Head Affairs | Profile | |
| LLM BSc | Vice Operations | Profile | |
| Ido Morpurgo | VP Operations | Profile | |
| Nir Livneh | VP Affairs | Profile |
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.